Clinical Trial Update: A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1% [Phase 3]

View source ↗

Summary

This is a Phase 3 clinical trial update describing a study that compares nivolumab plus relatlimab with chemotherapy against pembrolizumab plus chemotherapy for…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• KEYTRUDA (PEMBROLIZUMAB)
• OPDIVO (nivolumab)
• Relatlimab (relatlimab)

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: Non-small Cell Lung Cancer | Phase 3 | Status: RECRUITING